BioSpace News Archive

MYR Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization (CMA) for the medicinal product HEPCLUDEX® (bulevirtide, formally known as Myrcludex B).

According to the latest market report published by Persistence Market Research, titled “Asia Pacific Alopecia Treatment Market: Industry Analysis and Forecast (2016–2024)”, revenue from the Asia Pacific alopecia treatment market is expected to expand at a CAGR of 6.6% during the forecast period 2016 – 2024.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will expand its robust menu of ready-to-use Simoa® kits to include tau phosphorylated at threonine 181 (p-tau181), a highly specific biomarker for the study of Alzheimer’s disease pathology, in cerebral spinal fluid (CSF), serum and plasma.

Persistence Market Research (PMR) delivers key insights on the global cell free protein expression market in its upcoming report titled, “Cell Free Protein Expression Market: Global Industry Analysis and Forecast, 2016–2024”.

According to the latest market report published by Persistence Market Research titled “Diabetic Gastroparesis Treatment Market: Global Industry Analysis and Forecast, 2016 – 2024”, revenue from the global diabetic gastroparesis treatment market is projected to register a CAGR of 4.1% during the forecast period (2016–2024).

According to the latest market report published by Persistence Market Research titled “Global Fluoroscopy & C – Arms Market: Industry Analysis and Forecast, 2016 – 2024”, the global Fluoroscopy and C – Arms market is expected to exhibit a CAGR of 4.5% during the forecast period 2016–2024.

Rockland Immunochemicals Inc. has developed a critical antibody reagent essential to antibody tests used to determine SARS-CoV-2 exposure for patients suspected to have contracted COVID-19.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders,

The Association of Dental Support Organizations, its members and supported dental practices thank and applaud Northeast Delta Dental, Delta Dental of Connecticut, Delta Dental of New Jersey, Principal, Unum and United Concordia for their recognition and appreciation of the added burden the increased use of personal protective equipment during the COVID-19 pandemic has caused dental offices, by providing reimbursement for these services.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences